trial

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

NCTId NCT01511510
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 39 (actual)
Sponsored by Biogen
Primary completion 2011-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
39 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2011-06
Primary completion
2011-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-04958242

Sponsors

BiogenLead Sponsor

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
39
Phase
PHASE1
Primary Completion Date
2011-11
Status
COMPLETED
relationships
The graph out of here
drug
PF-04958242
drug
lead_sponsor
Biogen
company
indication
Schizophrenia
indication
Schizophrenia
indication